VOYAGER THERAPEUTICS INC. - COMMON STOCK

Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference

28 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

07 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Participate in Upcoming Investor Conferences

09 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors

14 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

08 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

01 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

11 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target

04 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy

03 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Participate in Upcoming Investor Conferences

27 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

07 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

04 Aug 2022 16:01:00 By Nasdaq GlobeNewswire